Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 26, 2026, disclosing two open-market sales of ordinary shares totaling 10,000 shares executed on August 19 and August 24, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- First sale: 5,000 ordinary shares sold on August 19, 2026, at $8.2 per share.
- Second sale: 5,000 ordinary shares sold on August 24, 2026, at $8.8 per share.
- Total shares sold: 10,000 ordinary shares across the two transactions.
- Remaining ownership: 172,171 ordinary shares held directly following the reported transactions.
- Trading plan: Both transactions were made pursuant to a duly adopted trading plan under Rule 10b5-1(c), according to the filing.
- Reporting person: Abhimanyu Verma, identified in the filing as Chief Technology Officer of SOPHiA GENETICS SA.
SOPHiA GENETICS CTO Share Sales: Transaction Details and Remaining Ownership
According to the Form 4 filed with the SEC on August 26, 2026, Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, disposed of ordinary shares on two separate dates. On August 19, 2026, Verma sold 5,000 ordinary shares at a price of $8.2 per share, reducing his directly held position to 177,171 shares. Five days later, on August 24, 2026, he sold an additional 5,000 ordinary shares at $8.8 per share, bringing his directly held beneficial ownership to 172,171 ordinary shares.
Both transactions carry transaction code "S," indicating open-market sales, and both are reported as direct ownership. The filing notes in its explanation of responses that each transaction "was made pursuant to duly adopted trading plan under Rule 10b5-1(c)." No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Elimara Brunetto as attorney-in-fact for Abhimanyu Verma and dated August 26, 2026.
SOPHiA GENETICS SA is listed on NASDAQ under the ticker symbol SOPH, as indicated on the filing's cover. The company's registered address for the reporting person is listed as La Piece 12, Rolle, Switzerland.
What Was Disclosed
The filing disclosed two sales of ordinary shares by SOPHiA GENETICS SA's Chief Technology Officer, totaling 10,000 shares sold on August 19 and August 24, 2026, both executed under a pre-established Rule 10b5-1(c) trading plan, leaving the officer with 172,171 directly held shares.




Please wait processing your request...